Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007–2018

Zhenhan Li¹, Guoqi Zhu², Guo Chen¹, Mei Luo¹, Xuebo Liu²†, Zhongpei Chen† and Jun Qian²*†

Abstract

Background  Lipid-lowering therapy is important, and the distribution of lipid levels and the incidence of hyperlipidemia may vary in different subgroups of the population. We aimed to explore the distribution of lipid levels and the prevalence of hyperlipidemia in subpopulations with subgroup factors, including age, sex, race, and smoking status.

Methods  Our study used data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018, ultimately enrolling and analyzing 15,499 participants. A cross-sectional analysis was performed to assess the distribution of lipids and prevalence of hyperlipidemia in subpopulations, and multifactorial logistic regression analyses were performed for the prevalence of hyperlipidemia, adjusted for age, sex, race and smoking status.

Results  Blacks had significantly lower mean serum total cholesterol and triglycerides and higher serum high-density lipoprotein cholesterol (HDL-C) than whites (P< 0.001). In contrast, Mexican Americans had markedly higher mean serum triglycerides and lower serum HDL-C than whites (P< 0.001). Furthermore, the prevalence of hypercholesterolemia and hypertriglyceridemia was lower in blacks than in whites (P= 0.003 and P< 0.001, respectively), while the prevalence of hypertriglyceridemia was significantly higher in Mexican Americans than in whites (P= 0.002). In addition, total cholesterol and triglyceride levels were significantly higher in women aged 65 years or older and markedly higher than in men in the same age group (P< 0.001). In addition, overall mean total cholesterol, triglyceride, and low-density lipoprotein cholesterol (LDL-C) levels were higher in smokers than in nonsmokers (P= 0.01, P< 0.001, and P= 0.005, respectively).

Conclusion  Based on NHANES data, the mean lipid levels and prevalence of hyperlipidemia differed by sex, age, race, and smoking status.

Keywords  Hyperlipidemia, Lipid levels, Age, Sex, Race, Smoking status, NHANES database

¹Jun Qian, Zhongpei Chen and Xuebo Liu contributed equally and share the corresponding author.

*Correspondence:
Jun Qian
jgsqianjun@163.com

1Department of Endocrinology, Chongqing Hospital Of Traditional Chinese Medicine, Chongqing, China
2Department of Cardiology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Hyperlipidemia is defined as a higher-than-normal level of one or more lipids in plasma, which is clinically classified as hypercholesterolemia, hypertriglyceridemia, mixed hyperlipidemia, and high-density lipoproteinemia in the clinic [1, 2]. Epidemiological studies and clinical trials have confirmed that elevated low-density lipoprotein cholesterol (LDL-C), cholesterol, or triglycerides are the major contributors to atherosclerotic cardiovascular disease [3, 4]. Generally, the risk of atherosclerotic events increased significantly when plasma total cholesterol levels exceeded 240 mg/dl or triglyceride levels exceeded 200 mg/dl [5, 6]. Furthermore, hyperlipidemia-induced atherosclerosis increases morbidity and mortality in a quiet modality, including myocardial infarction, cerebral infarction, and peripheral vascular disease [4]. In patients with hyperlipidemia, the incidence of cardiovascular events remains high even when treated with secondary or primary prevention therapy, such as statins, where elevated triglyceride levels can serve as an independent marker of increased risk of ischemic events [7]. In the United States (US), Canadian and European guidelines for the management of hypercholesterolemia, LDL-C is the primary target for lipid-lowering therapy, based on which hypercholesterolemia is the most important pathogenic factor in atherosclerotic cardiovascular disease [8].

The American Heart Association Task Force on Clinical Practice Guidelines proposed individualized management and lifestyle interventions that consider risk factors while lowering LDL-C with high-intensity statins with reference LDL-C thresholds, including 70 mg/dL (1.8 mmol/L) and 100 mg/dL (2.6 mmol/L), and age points of 40 and 75 years [9]. The guidelines related to hyperlipidemia are graded as low risk, moderate risk, moderate-high risk, and high risk in that order based on a comprehensive assessment of risk factors (e.g., sex, age, smoking, hypertension, coronary heart disease, etc.), cholesterol and triglyceride levels [9, 10]. In addition, the corresponding treatment is administered according to the risk level after hyperlipidemia assessment to reduce the occurrence of cardiovascular events and other complications [11, 12]. However, race/ethnicity can influence the estimation of atherosclerotic cardiovascular disease risk, treatment intensity, and even the use of lipid-lowering drugs, such as the higher risk of atherosclerotic cardiovascular disease in South Asians, greater statin sensitivity in East Asians, and higher prevalence of hypertension in blacks [13]. Therefore, the specific distribution of blood lipid levels by race, sex, and age is still unclear, and current treatments based on risk stratification of lipids also do not consider differences in those factors [14, 15].

The objective of our study was to investigate the distribution of blood lipid levels by race, sex, age, and smoking status in the population based on data from the National Health and Nutrition Examination Survey (NHANES): 2007–2018. These data will refine lipid-related information for different subpopulations and provide a reference for more accurate cardiovascular event prevention treatment in different populations.

Methods

Data collection

NHANES is a representative series of cross-sectional studies designed to monitor the health status of the US population. NHANES data consist of interviews, examinations, and laboratory data collected from a complex, multistage, stratified, aggregated probability sample of civilians and nonhospital personnel [16]. The institutional Review Board of the National Center for Health Statistics (NCHS) approved the study protocol, and all participants provided written informed consent. In NHANES from 1999 to 2018, participation in-home interviews was 52–84%, and the percentage in mobile medical examinations was 49–80%. Our study included adult participants aged 18 years or older in NHANES from 2007 to 2018. The exclusion criteria included the following: (1) participants under the age of 18; (2) participants who did not attend screening centers; and (3) participants with missing lipid values.

Sociodemographic characteristics, laboratory testing, and definition

Participants reported age, sex (male or female), race (white, black, Mexican-American), and smoking status (smoker or nonsmoker). NHANES organizers collected 3 ml or 5 ml of K3 EDTA anticoagulant whole blood from all participants 18 years of age or older using established venipuncture protocols and procedures. Total cholesterol, triglycerides, LDL-C, and serum high-density lipoprotein cholesterol (HDL-C) values were measured enzymatically. Hypercholesterolemia was defined as fasting total cholesterol values ≥240 mg/dl. High triglycerides were defined as fasting triglyceride values ≥200 mg/dl. Smokers were defined as smoking more than 100 cigarettes in life and smoking some days or every day, while nonsmokers smoked less than 100 cigarettes in life.

Statistical analysis

Our analyses used a weighted sample and took into account stratification and clustering designed to derive estimates of the U.S. population [17]. All statistical analyses were carried out using R software (version 4.1.0; http://www.R-project.org, R Foundation for Statistical Computing, Vienna, Austria). The unadjusted frequency distribution of blood lipid values and unadjusted prevalence of hyperlipidemia associated with age, sex, race, and smoking status were identified. We used linear regression
Mean blood lipid values among sex, age, and ethnic group

Of the 36,580 participants aged 18 or older who were asked to attend the mobile examination center, 1,418 did not come to the screening center, and 19,663 had missing blood lipid values. A total of 15,499 NHANES participants were enrolled in the study, which represented 104.4 million United States residents. We used linear regression to compare age-adjusted and sex-adjusted blood lipids, where age was modeled as a continuous variable. We also compared the adjusted mean blood lipids of smokers and nonsmokers. Multivariate logistic regression analysis was performed for the prevalence of hypercholesterolemia and hyperlipidemia, adjusting for age, sex, and ethnic groups. More complex models including ethnicity and sex were also tested, and different age classifications were considered.

Results

Mean blood lipid values among sex, age, and ethnic group

The prevalence of hypercholesterolemia and hypertriglyceridemia, with a weighted prevalence of 11.5% (95% CI, 10.6–12.5%) and 10.4% (CI, 9.4–11.4%), representing an estimated 12.05 million and 10.84 million Americans, respectively. Hypercholesterolemia and hypertriglyceridemia were present in 12.2% (CI, 11.3–13.1%) and 10.9% (CI, 9.8–11.9%) of white participants, 9.4% (CI, 8.3–10.4%) and 4.4% (5.1% CI, 3.7%) of black participants, and 10.1% (CI, 8.5–11.7%) and 13.2% (CI, 11.5–14.5%) of Mexican-American participants (Table 4). Among ethnic groups, males were more likely to have hypertriglyceridemia: white males 13.0% versus white females 8.9%, black males 6.9% versus black females 3.0% and females 2.2% versus white females 1.5%.

Table 1 Age-adjusted and sex-adjusted mean blood lipid levels by using linear regression

| Variable   | Mean Value | Mean Difference | p value |
|------------|------------|----------------|---------|
| Total cholesterol |            |                |         |
| Whites     | 191.6 (190.1–193.1) | Ref.            | /       |
| Blacks     | 186.2 (184.6–187.9) | 4.0 (2.0–5.9)  | <0.001  |
| Mexicans   | 189.0 (186.7–191.4) | 0.9 (-1.6–3.5) | 0.47    |
| Triglyceride |            |                |         |
| Whites     | 117.4 (114.9–119.8) | Ref.            | /       |
| Blacks     | 89.2 (86.7–91.7)   | 24.7 (21.6–27.8)| <0.001  |
| Mexicans   | 124.8 (121.2–128.4)| 11.9 (7.6–16.2) | <0.001  |
| HDL-C      |            |                |         |
| Whites     | 54.9 (54.3–55.5)   | Ref.            | /       |
| Blacks     | 57.2 (56.5–57.9)   | 2.2 (0.8–3.6)  | <0.001  |
| Mexicans   | 50.9 (50.2–51.6)   | 3.0 (2.0–4.0)  | <0.001  |
| LDL-C      |            |                |         |
| Whites     | 113.3 (112.1–114.5)| Ref.            | /       |
| Blacks     | 111.2 (109.5–112.8)| 1.3 (-0.5–3.1) | 0.19    |
| Mexicans   | 113.2 (111.1–114.5)| 1.5 (-0.7–3.7) | 0.21    |

Means (95% CIs) are given from a weighted analysis adjusted for age and sex. Abbreviations: HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol, Ref, Reference.
2.5%, Mexicans-American males 14.3% versus Mexicans-American females 9.2%. Nevertheless, the proportion of females with hypercholesterolemia was higher than that of males. In every age and sex category, black participants were less likely to have hypertriglyceridemia than white participants, and hypertriglyceridemia was more common among Mexican-American participants than among white participants.

Multivariate logistic regression analysis was performed for the prevalence of hyperlipidemia, adjusted for sex, age, and race (Table 4). Black participants were less likely to have hypercholesterolemia ($P=0.003$) or hypertriglyceridemia ($P<0.001$) than white participants. Mexican-Americans had no significant difference in the prevalence of hypercholesterolemia ($P=0.70$) but had a significantly higher prevalence of hypertriglyceridemia ($P=0.002$) than white participants. Males had less hypercholesterolemia ($P<0.001$) but more hypertriglyceridemia ($P<0.001$) than females. The prevalence of hyperlipidemia peaked from the age of 35 to 65 years and generally decreased after the age of 65 years. In independent logistic regression analysis adjusted for sex, age, and race, smokers had significantly higher percentages of hypercholesterolemia ($P=0.002$) and hypertriglyceridemia ($P<0.001$) than nonsmokers.

**Discussion**

In this analysis of nationally representative data, the mean lipid levels and prevalence of hyperlipidemia were different among sex, age, smoking status, and ethnic group. The mean values of serum total cholesterol and triglycerides in black participants were significantly lower than those in white participants, and serum HDL-C was higher than in white participants. Mexican-American participants had considerably higher average serum triglycerides and lower serum HDL-C than white participants.

![Fig. 1](image_url) The actual percentage and number of participants with different mean lipid values based on gender and age.
Black participants had a notably lower prevalence of hypercholesterolemia or hypertriglyceridemia than white participants, and Mexican-American participants had a significantly higher prevalence of hypertriglyceridemia than white participants. Similarly, a CARDIA study of long-term trends in lipid levels in whites and blacks, men and women in four U.S. communities followed by a multifactorial regression stratified by race and sex analysis found that LHD-C increased with age, except for black women who consistently maintained lower LDL-C levels, while triglycerides showed an unfavorable long-term upward trend in white women [18]. Studies on the association between age and lipid levels are still controversial, for example, in Spain, France, Finland, and Australia, showing a decreasing trend in total cholesterol and/or LHD-C with increasing age and use of lipid-lowering drugs [19–22]. However, investigations in countries such as Japan and India have shown an increasing trend in age-adjusted mean total cholesterol and triglycerides over the same period, despite an increase in the use of lipid-lowering drugs [23, 24]. In our study, females had higher cholesterol and triglyceride levels than males in the population aged 65 years and older, regardless of other factors. Compared to females, males had less hypercholesterolemia but more hypertriglyceridemia, with this difference using age 65 as the cutoff. In addition, smokers had higher total cholesterol, triglyceride, and LDL-C levels and lower HDL-C levels than non-smokers. The prevalence of hypercholesterolemia and hypertriglyceridemia was significantly higher in smokers than in nonsmokers. Among them, smoking had the greatest effect on elevated triglyceride levels in Mexican-American participants, with a smaller effect in white participants and the least effect in black participants.

Many projects have researched the incidence and prevalence of hyperlipidemia, which is associated with many metabolic disorders in the clinic. Sparkar et al. suggested that hyperlipidemia is associated with an increased risk of nonalcoholic fatty liver disease in blacks and whites, affecting black adults in particular [25]. Among women with early breast cancer, hyperlipidemia was more prevalent in black women than in white women (28% versus 18%; \(P<0.02\)) [26]. However, a national cross-sectional study in South Africa showed that black African men (0.64, 0.49–0.84) and women (0.52, 0.43–0.62) had significantly lower odds of hypercholesterolemia than white men and women, respectively [27]. Similarly, hypercholesterolemia was significantly higher in white patients with non-ST-segment elevation myocardial infarction than in patients of color (49% versus 34%, \(P<0.001\)), including black, Asian, and ethnic minority patients [28]. In addition, among South African children and adolescents, other ethnic groups were more likely to have hypertriglyceridemia (1.94, 0.99–3.78) and low HDL-C levels than whites and blacks [29]. In another study, the prevalence of hypertriglyceridemia was found to be significantly lower in non-Hispanic black women than in non-Hispanic whites and Hispanics (5.1 versus 28.3 versus 30.5%, \(P<0.01\), respectively) [30]. The findings of the current studies are contradictory, and there is not a relatively consistent conclusion. Moreover, the current studies are limited to a specific population, and there is no analysis of racial differences in blood lipids in the general population. However, one thing is certain is that there are differences in the distribution of lipid levels in different subpopulations.

Our study suggests that lipid levels vary by race, sex, age, smoking, etc. In general, blacks have significantly

### Table 2 Mean blood lipid values, by age, sex, and ethnic group

|                | Whites          | Blacks          | Mexicans        |
|----------------|-----------------|-----------------|-----------------|
| **Total cholesterol** |                 |                 |                 |
| Males <65y     | 188.1(185.9–190.3) | 185.9           | 191.5           |
|                 | (183.4–188.5)  |                                  | (188.4–194.7)  |
| Males ≥65y     | 174.9(171.8–178.1)†| 173.3(168.5–178.1)‡ | 177.7(171.6–183.7)‡ |
|                | (168.4–176.3)  |                                  | (177.5–185.1)  |
| Females <65y   | 195.9(194.0–197.7) | 186.5           | 187.1           |
|                | (184.1–188.5)  |                                  | (184.1–190.5)  |
| Females ≥65y   | 202.8(199.3–206.3)§| 194.7(188.8–200.7)§ | 189.9(185.6–194.2)§ |
| **Triglyceride** |                 |                 |                 |
| Males <65y     | 123.7(120.1–127.4) | 98.9(95.1–102.6) | 133.9           |
|                | (120.0–138.8)  |                                  | (129.0–138.8)  |
| Males ≥65y     | 120.1(115.0–125.2)‡| 91.9(86.0–97.9) †| 127.4(114.9–140.0) †|
|                | (114.9–128.4)  |                                  | (110.4–137.7)  |
| Females <65y   | 108.3(104.7–111.8)¶ | 81.1(78.5–83.8) §| 113.5           |
|                | (104.0–117.7)  |                                  | (104.0–117.7)  |
| Females ≥65y   | 123.4(118.5–128.3)¶ | 90.3(84.9–95.7) ¶| 125.2(126.4–144.0) ¶ |
| **HDL-C**      |                 |                 |                 |
| Males <65y     | 48.5(47.8–49.2) | 53.1(52.2–54.0) | 47.2(46.3–48.1) |
|                | (51.9–49.2)     |                                  | (50.5–49.5)    |
| Males ≥65y     | 51.0(49.4–52.6) | 54.9(53.2–56.5) | 50.1(47.2–53.1) |
|                | (49.7–54.6)     |                                  | (49.7–55.3)    |
| Females <65y   | 59.4(58.5–60.4) | 59.7(58.6–60.8) | 54.3(53.4–55.1) |
|                | (57.9–60.4)     |                                  | (53.8–55.5)    |
| Females ≥65y   | 63.5(61.8–65.1) | 63.6(61.6–65.7) | 57.4(55.1–59.7) |
| **LDL-C**      |                 |                 |                 |
| Males <65y     | 114.8(113.0–116.6) | 113.1           | 117.5           |
|                | (110.7–115.5)  |                                  | (114.7–120.4)  |
| Males ≥65y     | 100.0(97.2–102.7)§ | 100.0(95.7–104.3) § | 102.1           |
|                | (96.8–107.4)   |                                  | (96.8–107.4)   |
| Females <65y   | 114.8(113.3–116.2) | 110.5           | 110.1           |
|                | (108.4–112.7)  |                                  | (107.4–112.9)  |
| Females ≥65y   | 114.6(111.5–117.7)§ | 113.0           | 105.5           |
|                | (107.3–118.8)  |                                  | (101.5–109.4)  |

Means (95% CIs) are given from a weighted analysis adjusted for age and sex

* \(P<0.05\) Females ≥65y compared with females <65 y

† \(P<0.05\) Males ≥65y compared with males <65 y

‡ \(P<0.05\) Females <65y compared with males <65 y

§ \(P<0.05\) Females ≥65y compared with males ≥65 y
lower lipid levels than other populations, and smokers have significantly higher lipids than nonsmokers. In addition, age also affects lipid levels, especially hormonal changes in women after menopause. Therefore, the diagnosis and treatment of hyperlipidemia should be done concerning the lipid levels of subpopulations, not the general population.

### Strengths and Limitations

Our study is the first to describe the distribution of blood lipids across ethnic, gender, and age groups. Besides, the prevalence of hypercholesteremia and hypertriglyceridemia across different ethnic, gender, and age were also explored. However, there were several limitations about this study. Our study did not include diet and medication use in the comparative analysis, and they may have influenced the lipid and study results. In addition, the data in this study were surveyed for the US population, and geographic characteristics such as climate and economy may have affected the results accordingly, so we may consider adding relevant lipid data from other geographic populations in the future to improve the accuracy of the data analysis.

### Conclusion

Distribution of population lipid levels and prevalence of hyperlipidemia based on differences in age, sex, race, and smoking status. Therefore, our analysis suggested a new view that the diagnosis and treatment of hyperlipidemia should be more accurate by referring to the lipid levels of subpopulations rather than those of the general population.

---

### Table 3  Comparative Mean Blood Lipid Values in Smokers and Non-smokers

| Variable          | Smokes  | Nonsmokers | Mean Difference between Smokers and Nonsmokers | p value* † |
|-------------------|---------|------------|-----------------------------------------------|-----------|
| **Total cholesterol** |         |            |                                               |           |
| All               | 191.6(189.3,193.8) | 190.8(189.7,192.0) | 2.9(0.5–5.3) | 0.01          |
| Whites            | 192.5(189.4,195.5) | 191.8(190.3,193.3) | 3.1(-0.03-6.2) | 0.06          |
| Blacks            | 184.8(181.6,188.1) | 187.5(185.5,189.6) | 1.9(-1.8,5.6) | 0.32          |
| Mexicans          | 192.7(187.7,197.7) | 189.2(186.9,191.6) | 3.2(-1.3-7.8) | 0.17          |
| **Triglyceride**  |         |            |                                               |           |
| All               | 125.1(121.1,129.1) | 113.0(111.0,115.0) | 13.6(9.5–17.7) | < 0.001      |
| Whites            | 127.0(122.0,132.1) | 115.4(112.9,117.9) | 14.7(9.4–20.0) | < 0.001      |
| Blacks            | 100.4(96.0,104.8)  | 85.8(82.9,88.7)   | 12.8(7.7–17.8) | < 0.001      |
| Mexicans          | 142.4(132.2,152.7) | 122.5(118.7,126.4) | 17.2(6.3–28.0) | < 0.001      |
| **HDL-C**         |         |            |                                               |           |
| All               | 51.5(50.7,52.4)    | 55.3(54.8,55.8)   | 2.6(1.8–3.4)   | < 0.001      |
| Whites            | 51.4(50.3,52.5)    | 55.7(55.1,56.4)   | 3.4(2.3,4.6)   | < 0.001      |
| Blacks            | 56.0(54.6,57.4)    | 57.7(56.9,58.5)   | 0.5(-1.0,2.1)  | 0.51          |
| Mexicans          | 48.1(46.5,49.8)    | 51.3(50.6,52.1)   | 1.8(-0.2,3.7)  | 0.08          |
| **LDL-C**         |         |            |                                               |           |
| All               | 115.0(113.2,116.9) | 112.9(112.0,113.9) | 2.8(0.8–4.8)   | 0.005         |
| Whites            | 115.6(113.1,118.2) | 113.0(111.7,114.2) | 3.6(-0.8-6.4)  | 0.01          |
| Blacks            | 108.8(105.6,112.0) | 112.7(110.8,114.6) | 3.9(0.3,7.6)   | 0.04          |
| Mexicans          | 116.1(112.0,120.1) | 113.4(111.2,115.5) | 1.5(-2.2-5.3)  | 0.43          |

*The respective numbers of participants who smoked and those who did not smoke were 757 and 2296 for black- 1356 and 4847 for white- and 331 and 1990 for Mexican-American participants
†Comparisons of the means between smokers and nonsmokers- according to ethnicity and adjusted for age and sex
Fig. 2 The actual percentage and number of participants with different incidences of hyperlipidemia based on race and age.
Table 4  Prevalence of hypercholesterolemia and hypertriglyceridemia

| Ethnicity  | Hypercholesterolemia (%) (95% CI) | p value | Hypertriglyceridemia (%) (95% CI) | p value |
|-----------|----------------------------------|---------|----------------------------------|---------|
| Whites    | 12.2 (11.3–13.1)                 | Ref.    | 10.9 (9.8–11.9)                 | Ref.    |
| Blacks    | 9.4 (8.3–10.4)                   | 0.003   | 4.4 (3.7–5.1)                    | < 0.001 |
| Mexican   | 10.1 (8.5–11.7)                  | 0.70    | 13.2 (11.5–14.5)                 | 0.002   |
| Sex       |                                   |         |                                  |         |
| Female    | 13.7 (12.8–14.6)                 | Ref.    | 8.0 (7.0–9.0)                    | Ref.    |
| Male      | 9.2 (8.4–10.1)                   | < 0.001 | 12.9 (11.9–13.9)                 | < 0.001 |
| Age       |                                   |         |                                  |         |
| 18–24     | 2.8 (1.7–4.0)                    | Ref.    | 4.6 (3.5–5.8)                    | Ref.    |
| 25–34     | 7.1 (5.8–8.3)                    | < 0.001 | 7.8 (6.5–9.1)                    | < 0.001 |
| 35–44     | 11.3 (9.5–13.1)                  | < 0.001 | 12.9 (11.2–14.7)                 | < 0.001 |
| 45–54     | 15.9 (13.8–18.1)                 | < 0.001 | 11.9 (10.3–13.5)                 | < 0.001 |
| 55–64     | 16.1 (14.1–18.0)                 | < 0.001 | 12.6 (10.5–14.7)                 | < 0.001 |
| 65–74     | 13.4 (11.2–15.5)                 | < 0.001 | 11.4 (9.2–13.6)                  | < 0.001 |
| ≥ 75      | 11.7 (9.8–13.6)                  | < 0.001 | 8.6 (7.1–10.0)                   | < 0.001 |
| Smoke     |                                   |         |                                  |         |
| Yes       | 12.8 (11.2–14.3)                 | Ref.    | 13.4 (11.4–15.3)                 | Ref.    |
| No        | 11.4 (10.7–12.2)                 | 0.002   | 9.7 (9.0–10.5)                   | < 0.001 |

*Prevalence is estimated as the predicted marginals in the logistic regression analysis. The estimates for white-black and Mexican-American participants are adjusted for age and sex.

References

1. Hill MF, Bordini B. Hyperlipidemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 8, 2022.
2. Kari S. Epidemiology and management of hyperlipidemia. Am J Manag Care. 2017;23(9 Suppl):139–48.
3. Simha V. Management of hypertriglyceridemia. BMJ. 2020;371:m3109. Published 2020 Oct 12. https://doi.org/10.1136/bmj.m3109.
4. Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56. Published 2019 Aug 16. https://doi.org/10.1038/s41572-019-0106-2.
5. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2001;106(25):3143–421.
6. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292–333. https://doi.org/10.1161/CIR.0b013e3182107266.
7. Bhattacharya S, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. https://doi.org/10.1056/NEJMoa1812792.
8. Johannesen CDB, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol. 2021;77(11):1439–50. https://doi.org/10.1016/j.jacc.2021.01.027.
9. Michos ED, McEvoy JW, Blumenthal RS. Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2019;381(16):1557–67. https://doi.org/10.1056/NEJMra1806939.
10. National Clinical Guideline Centre (UK). Lipid Modification—Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. London: National Institute for Health and Care Excellence (UK); July 2014.
11. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016, 37(29):2315–2381. https://doi.org/10.1093/eurheartj/ehw106.
12. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934. https://doi.org/10.1016/j.jacc.2013.11.002.
13. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139(25):e1082–143. https://doi.org/10.1161/CIR.0000000000006255.
14. Navar-Boggan AM, Peterson ED, D’Agostino RB, et al. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation. 2015;131(5):451–8. https://doi.org/10.1161/CIR.0000000000006255.
15. Martin SS, Michos ED. Mapping hyperlipidemia in young adulthood to coronary risk: Importance of cumulative exposure and how to stay young. Circulation. 2015;131(5):445–7. https://doi.org/10.1161/CIRCULATIONAHA.114.014433.
16. Johnson CL, Paulose-Ram R, Ogden CL, et al. National health and nutrition examination survey: analytic guidelines, 1999–2010. Vital Health Stat 2. 2011(63):1–24.
17. Ingram DD, King DR Jr, Wong ND, Kiefe CI. Twenty-Five Year Secular Trends in Lipids and Modifiable Risk Factors in a Population-Based Biracial Cohort: The Coronary Artery Risk Development in Young Adults (CARDIA) Study, 1985–2011. J Am Heart Assoc. 2016;5(7):e003834. https://doi.org/10.1016/j. jaha.2016.08.013.
19. Serra-Majem L, Pastor-Ferrer MC, Castell C, et al. Trends in blood lipids and fat soluble vitamins in Catalonia, Spain (1992–2003). Public Health Nutr. 2007;10(11A):1379–88. https://doi.org/10.1079/PHN2007000985.

20. Ferrières J, Bongard V, Dallongeville J, et al. Trends in plasma lipids, lipoproteins and dyslipemias in French adults, 1996–2007. Arch Cardiovasc Dis. 2009;102(4):293–301. https://doi.org/10.1016/j.acvd.2009.02.002.

21. Vilkari JS, Juonala M, Raitakari OT. Trends in cardiovascular risk factor levels in Finnish children and young adults from the 1970s: The Cardiovascular Risk in Young Finns Study. Exp Clin Cardiol. 2006;11(2):83–8.

22. Hobbs MS, Knuiman MW, Briffa T, Ngo H, Jamrozik K. Plasma cholesterol levels continue to decline despite the rising prevalence of obesity: population trends in Perth, Western Australia, 1980–1999. Eur J Cardiovasc Prev Rehabil. 2008;15(3):319–324. https://doi.org/10.1097/HJR.0b013e3282f3c76b.

23. Iso H. Changes in coronary heart disease risk among Japanese. Circulation. 2008;118(25):2725–9. https://doi.org/10.1161/CIRCULATIONAHA.107.750117.

24. Gupta R, Guptha S, Agrawal A, et al. Secular trends in cholesterol lipoproteins and triglycerides and prevalence of dyslipemias in an urban Indian population. Lipids Health Dis. 2008;7:40. https://doi.org/10.1186/1476-511X-7-40.

25. Sarkar S, Lipworth L, Kabagambe EK, et al. A Description of Risk Factors for Nonalcoholic Fatty Liver Disease in the Southern Community Cohort Study: A Nested Case–Control Study. Front Nutr. 2020;7:71. Published 2020 May 21. https://doi.org/10.3389/fnut.2020.00071.

26. Nyrop KA, Damone EM, Deal AM, et al. Obesity, comorbidities, and treatment selection in Black and White women with early breast cancer. Cancer. 2021;127(6):922–30. https://doi.org/10.1002/cncr.35288.

27. Peer N, Balakrishna Y, de Villiers A, Naadso P. Differential associations of cardio-metabolic diseases by population group, gender and adiposity in South Africa. PLoS ONE. 2018;13(9):e0202899. https://doi.org/10.1371/journal.pone.0202899. Published 2018 Sep 27.

28. Moledina SM, Shoaib A, Weston C, et al. Ethnic disparities in care and outcomes of non-ST-segment elevation myocardial infarction: a nationwide cohort study [published online ahead of print, 2021 Apr 21]. Eur Heart J Qual Care Clin Outcomes. 2021; qcab030. https://doi.org/10.1093/ehjqcco/qcab030.

29. Negash S, Ayemang C, Matsha TE, et al. Differential prevalence and associations of overweight and obesity by gender and population group among school learners in South Africa: a cross-sectional study. BMC Obes. 2017;4:29. https://doi.org/10.1186/s40608-017-0165-1. Published 2017 Jul 17.

30. Engmann L, Jin S, Sun F, et al. Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype. Am J Obstet Gynecol. 2017;216(5):493.e. https://doi.org/10.1016/j.ajog.2017.01.003.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.